[
  {
    "ts": null,
    "headline": "Apple Tops the List of Best-Managed Companies of 2024",
    "summary": "Apple Tops the List of Best-Managed Companies of 2024",
    "url": "https://finnhub.io/api/news?id=8f3fbce5daff4b28c673caa376a268e010476c547c98641273093eccfaa10535",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733692440,
      "headline": "Apple Tops the List of Best-Managed Companies of 2024",
      "id": 131873278,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "Apple Tops the List of Best-Managed Companies of 2024",
      "url": "https://finnhub.io/api/news?id=8f3fbce5daff4b28c673caa376a268e010476c547c98641273093eccfaa10535"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Announces Data Highlighting That DARZALEX FASPRO (Daratumumab and Hyaluronidase-fihj) Based Regimens Improve Overall and Sidual Disease",
    "summary": "Johnson & Johnson announced data highlighting that DARZALEX FASPRO® -based regimens improve overall and sustained minimal residual disease negativity rates and progression-free survival in patients...",
    "url": "https://finnhub.io/api/news?id=da40104a4c18cee864d63e2f97cf21f36afa11e42556146617304245f9ee098d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733686200,
      "headline": "Johnson & Johnson Announces Data Highlighting That DARZALEX FASPRO (Daratumumab and Hyaluronidase-fihj) Based Regimens Improve Overall and Sidual Disease",
      "id": 131865317,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced data highlighting that DARZALEX FASPRO® -based regimens improve overall and sustained minimal residual disease negativity rates and progression-free survival in patients...",
      "url": "https://finnhub.io/api/news?id=da40104a4c18cee864d63e2f97cf21f36afa11e42556146617304245f9ee098d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Announces Data from the Phase 3 Acquisitions",
    "summary": "Johnson & Johnson announced data highlighting that DARZALEX FASPRO -based regimens improve overall and sustained minimal residual disease negativity rates and progression-free survival in patients...",
    "url": "https://finnhub.io/api/news?id=53c81f8b6fcb35cfa6081f65b3b2654ad610c5fced1f9fc1f54b10ce0366b186",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733686200,
      "headline": "Johnson & Johnson Announces Data from the Phase 3 Acquisitions",
      "id": 131865316,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced data highlighting that DARZALEX FASPRO -based regimens improve overall and sustained minimal residual disease negativity rates and progression-free survival in patients...",
      "url": "https://finnhub.io/api/news?id=53c81f8b6fcb35cfa6081f65b3b2654ad610c5fced1f9fc1f54b10ce0366b186"
    }
  },
  {
    "ts": null,
    "headline": "Advertising Firms Omnicom and Interpublic Nearing Merger That Would Reshape Industry",
    "summary": "A deal would create the world’s largest advertising company, with net revenue of more than $20 billion, topping WPP’s $15.1 billion.",
    "url": "https://finnhub.io/api/news?id=2b2faff034055a77484820c4602242ece968a361e442ac38f385950db80fa3cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733675220,
      "headline": "Advertising Firms Omnicom and Interpublic Nearing Merger That Would Reshape Industry",
      "id": 131861926,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A deal would create the world’s largest advertising company, with net revenue of more than $20 billion, topping WPP’s $15.1 billion.",
      "url": "https://finnhub.io/api/news?id=2b2faff034055a77484820c4602242ece968a361e442ac38f385950db80fa3cf"
    }
  },
  {
    "ts": null,
    "headline": "TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma",
    "summary": "Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. The MajesTEC-5 (Abstract #493) and MajesTEC-4 (Abstract #494) studies establish the potential of TECVAYLI® for use in newly diagnosed patients, with promising efficacy and a tolerable safety profile. These data were highlighted as oral presentations at the 2024 Americ",
    "url": "https://finnhub.io/api/news?id=f175b7e4f4d6ed72c15da2e84dbe04a370d773afb59b251658030c5fffeed2e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733679180,
      "headline": "TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma",
      "id": 131862860,
      "image": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. The MajesTEC-5 (Abstract #493) and MajesTEC-4 (Abstract #494) studies establish the potential of TECVAYLI® for use in newly diagnosed patients, with promising efficacy and a tolerable safety profile. These data were highlighted as oral presentations at the 2024 Americ",
      "url": "https://finnhub.io/api/news?id=f175b7e4f4d6ed72c15da2e84dbe04a370d773afb59b251658030c5fffeed2e7"
    }
  },
  {
    "ts": null,
    "headline": "DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced data from the Phase 3 AQUILA study showing that DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) significantly delayed progression from high-risk smoldering multiple myeloma (SMM) to active multiple myeloma (MM) and extended overall survival compared to the current standard of care of active monitoring.1 The data were presented for the first time as an oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting (Abstract #7",
    "url": "https://finnhub.io/api/news?id=6754c6fb5fe0372403316b908189d252de76368c389661d7a55276bbbc66c310",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733674860,
      "headline": "DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma",
      "id": 131862862,
      "image": "https://media.zenfs.com/en/prnewswire.com/98a69363438bceaa4d51faba78e29c5c",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced data from the Phase 3 AQUILA study showing that DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) significantly delayed progression from high-risk smoldering multiple myeloma (SMM) to active multiple myeloma (MM) and extended overall survival compared to the current standard of care of active monitoring.1 The data were presented for the first time as an oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting (Abstract #7",
      "url": "https://finnhub.io/api/news?id=6754c6fb5fe0372403316b908189d252de76368c389661d7a55276bbbc66c310"
    }
  },
  {
    "ts": null,
    "headline": "Genmab Is Too Attractive To Ignore",
    "summary": "Learn why Genmab's shares are down but poised for growth in the long-term with strong revenue projections and pipeline expansion.",
    "url": "https://finnhub.io/api/news?id=d912f334868b203a0634e2f77f33edcf109aefc7a033a85c3cbbd79a89f99e63",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733645529,
      "headline": "Genmab Is Too Attractive To Ignore",
      "id": 131860791,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/530977027/image_530977027.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Learn why Genmab's shares are down but poised for growth in the long-term with strong revenue projections and pipeline expansion.",
      "url": "https://finnhub.io/api/news?id=d912f334868b203a0634e2f77f33edcf109aefc7a033a85c3cbbd79a89f99e63"
    }
  }
]